{"id":20406,"date":"2023-03-27T12:03:00","date_gmt":"2023-03-27T04:03:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20406"},"modified":"2025-01-01T12:25:01","modified_gmt":"2025-01-01T04:25:01","slug":"akeso-biopharma-and-lanova-medicines-collaborate-on-ak112-and-lm-302-combo-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20406","title":{"rendered":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors"},"content":{"rendered":"\n

China-based Akeso Biopharma (HKG: 9926<\/a>) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso’s AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova’s LM-302, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). The trial will focus on general solid tumor types.<\/p>\n\n\n\n

Phase II Trial and Investigator-Initiated Studies in Mainland China<\/strong>
The study will be conducted in mainland China, including a Phase II trial in advanced digestive tract tumors, along with investigator-initiated trials. The aim is to determine the dosage, administration frequency, safety, and efficacy of the combined therapy.<\/p>\n\n\n\n

AK112: The World\u2019s First PD-1\/VEGF BsAb in Phase III Trials<\/strong>
Akeso’s in-house discovery, AK112, is the world\u2019s first PD-1\/VEGF BsAb to enter into Phase III trials. It blocks the PD-1 and VEGF pathways simultaneously, aiming to produce synergistic anti-tumor effects. AK112 has received three breakthrough therapy designations (BTDs) in China and is currently undergoing a Phase III clinical study in first-line PD-L1 positive non-small cell lung cancer (NSCLC) compared with Keytruda. Additionally, it is involved in a Phase III clinical study combined with chemotherapy in advanced non-squamous NSCLC with EGFR TKI resistant EGFR mutations. The drug has also been approved in China for a Phase III study in first-line advanced squamous NSCLC combined with chemotherapy.<\/p>\n\n\n\n

LM-302: Targeting CLDN18.2-Positive Tumor Cells<\/strong>
LM-302 can target CLDN18.2-positive tumor cells to deliver a small-molecule toxin. The drug has received three Orphan Drug Designations (ODDs) in the US for the treatment of pancreatic cancer, gastric or gastroesophageal junction cancer, and cholangiocarcinoma. LM-302 is undergoing Phase II clinical trials in China and Phase I clinical trials in the US and Australia. LaNova signed an agreement with US firm Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to out-license LM-302 for development and commercialization globally outside the Greater China and South Korea markets.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,360,16,29,1376,28],"class_list":["post-20406","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-akeso-biopharma","tag-cancer","tag-combination-therapy","tag-lanova-medicines","tag-multi-specific-antibodies"],"yoast_head":"\nAkeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso's AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova's LM-302, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). The trial will focus on general solid tumor types.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20406\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20406\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T04:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-01T04:25:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors\",\"datePublished\":\"2023-03-27T04:03:00+00:00\",\"dateModified\":\"2025-01-01T04:25:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Akeso Biopharma\",\"Cancer\",\"Combination therapy\",\"LaNova Medicines\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20406#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20406\",\"name\":\"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-27T04:03:00+00:00\",\"dateModified\":\"2025-01-01T04:25:01+00:00\",\"description\":\"China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso's AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova's LM-302, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). The trial will focus on general solid tumor types.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20406\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20406#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors - Insight, China's Pharmaceutical Industry","description":"China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso's AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova's LM-302, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). The trial will focus on general solid tumor types.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20406","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20406","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-27T04:03:00+00:00","article_modified_time":"2025-01-01T04:25:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20406#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20406"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors","datePublished":"2023-03-27T04:03:00+00:00","dateModified":"2025-01-01T04:25:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20406"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Akeso Biopharma","Cancer","Combination therapy","LaNova Medicines","Multi-specific antibodies"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20406#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20406","url":"https:\/\/flcube.com\/?p=20406","name":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-27T04:03:00+00:00","dateModified":"2025-01-01T04:25:01+00:00","description":"China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso's AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova's LM-302, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). The trial will focus on general solid tumor types.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20406#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20406"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20406#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20406"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20406\/revisions"}],"predecessor-version":[{"id":20407,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20406\/revisions\/20407"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}